National Bank of Canada
BHVN

National Bank of Canada’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

National Bank of Canada’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-201
Closed -$24K – 3122
2022
Q1 		$24K Hold
201
– – ﹤0.01% 2126
2021
Q4 		$28K Buy
+201
New +$25.6K ﹤0.01% 2078

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

National Bank of Canada's BHVN Position: Q2 2022 in Review

National Bank of Canada sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 201 shares — an estimated $24K sold.

National Bank of Canada first reported a position in BHVN in Q4 2021 and held it in 2 quarters. The position peaked at $28K in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • National Bank of Canada reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • National Bank of Canada sold 201 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $24K.
  • National Bank of Canada first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 2 quarters.
  • National Bank of Canada's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $28K in Q4 2021.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on National Bank of Canada's 13F filing for Q2 2022, filed 28 Jul 2022.